FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317134147> ?p ?o ?g. }

• W2317134147 abstract "You have accessJournal of UrologyBenign Prostatic Hyperlasia: Medical and Hormonal Therapy1 Apr 20131385 EFFECTS OF FINASTERIDE AND TADALAFIL COMBINATION THERAPY ON LOWER URINARY TRACT SYMPTOMS AND ERECTILE FUNCTION IN MEN WITH PROSTATIC ENLARGEMENT: A RANDOMIZED, PLACEBO-CONTROLLED 6-MONTH STUDY Sidney Glina, Claus Roehrborn, Ketan Kapadia, Alexey Plekhanov, Adil Esen, Sebastian Sorsaburu, Carsten Henneges, Hartwig Buettner, and Lars Viktrup Sidney GlinaSidney Glina Sao Paolo, Brazil More articles by this author , Claus RoehrbornClaus Roehrborn Dallas, TX More articles by this author , Ketan KapadiaKetan Kapadia St. Petersburg, FL More articles by this author , Alexey PlekhanovAlexey Plekhanov St Petersburg, Russian Federation More articles by this author , Adil EsenAdil Esen Konak, Turkey More articles by this author , Sebastian SorsaburuSebastian Sorsaburu Indianapolis, IN More articles by this author , Carsten HennegesCarsten Henneges Bad Homburg, Germany More articles by this author , Hartwig BuettnerHartwig Buettner Bad Homburg, Germany More articles by this author , and Lars ViktrupLars Viktrup Indianapolis, IN More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2739AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The 5-alpha reductase inhibitor (5-ARI) finasteride is indicated for symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. 5-ARIs may reduce long-term risk of urinary retention but increase risk of sexual dysfunction. Tadalafil, a phosphodiesterase 5 inhibitor, is indicated for erectile dysfunction (ED) and for signs and symptoms of BPH (lower urinary tract symptoms suggestive of BPH, LUTS/BPH). Effects of once daily tadalafil 5 mg or placebo coadministered with finasteride 5 mg were assessed over 26 weeks. METHODS Men ≥45 years old and naïve to 5-ARIs, with International Prostate Symptom Score (IPSS) ≥13, Qmax ≥4 to ≤15 mL/sec and prostate volume ≥30mL, were randomized to finasteride/placebo (N=350) or finasteride/tadalafil (N=346) following a 4-week placebo run-in. Efficacy measures were assessed using mixed models for repeated measures. RESULTS Baseline mean (SD) age was 63.7 (7.7) years, mean prostate volume was 49.4 (20.4) mL, and mean prostate-specific antigen was 2.4 (2.0) ng/ml. IPSS improved significantly (p<0.05) at 4, 12 (primary endpoint, trt. diff. -1.41, p=0.001), and 26 weeks for finasteride/tadalafil vs. finasteride/placebo. In sexually active men, the International Index of Erectile Function-Erectile Function (IIEF-EF) domain score improved significantly with finasteride/tadalafil vs. finasteride/placebo at each visit in both men with and without (post hoc analysis) baseline ED (Figure). Most adverse events (AEs) with finasteride/tadalafil were mild or moderate in severity, and there were few discontinuations due to AEs. In the finasteride/placebo and finasteride/tadalafil treatment groups, 5 vs. 0 patients reported decrease/loss of libido and 5 vs. 1 patient reported ED, respectively. CONCLUSIONS Urinary symptoms were reduced significantly more at each study visit with finasteride/tadalafil vs. finasteride/placebo. In sexually active men, erectile function improved significantly with tadalafil in men with ED and those without ED prior to starting finasteride. Finasteride/tadalafil was generally well tolerated, with fewer events of reduced libido or ED vs. finasteride/placebo. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e566-e567 Peer Review Report Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sidney Glina Sao Paolo, Brazil More articles by this author Claus Roehrborn Dallas, TX More articles by this author Ketan Kapadia St. Petersburg, FL More articles by this author Alexey Plekhanov St Petersburg, Russian Federation More articles by this author Adil Esen Konak, Turkey More articles by this author Sebastian Sorsaburu Indianapolis, IN More articles by this author Carsten Henneges Bad Homburg, Germany More articles by this author Hartwig Buettner Bad Homburg, Germany More articles by this author Lars Viktrup Indianapolis, IN More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2317134147 created "2016-06-24" @default.
• W2317134147 creator A5026494399 @default.
• W2317134147 creator A5039009446 @default.
• W2317134147 creator A5046756071 @default.
• W2317134147 creator A5052292682 @default.
• W2317134147 creator A5067684587 @default.
• W2317134147 creator A5069328349 @default.
• W2317134147 creator A5089047852 @default.
• W2317134147 creator A5090431664 @default.
• W2317134147 creator A5090483382 @default.
• W2317134147 date "2013-04-01" @default.
• W2317134147 modified "2023-09-27" @default.
• W2317134147 title "1385 EFFECTS OF FINASTERIDE AND TADALAFIL COMBINATION THERAPY ON LOWER URINARY TRACT SYMPTOMS AND ERECTILE FUNCTION IN MEN WITH PROSTATIC ENLARGEMENT: A RANDOMIZED, PLACEBO-CONTROLLED 6-MONTH STUDY" @default.
• W2317134147 doi "https://doi.org/10.1016/j.juro.2013.02.2739" @default.
• W2317134147 hasPublicationYear "2013" @default.
• W2317134147 type Work @default.
• W2317134147 sameAs 2317134147 @default.
• W2317134147 citedByCount "0" @default.
• W2317134147 crossrefType "journal-article" @default.
• W2317134147 hasAuthorship W2317134147A5026494399 @default.
• W2317134147 hasAuthorship W2317134147A5039009446 @default.
• W2317134147 hasAuthorship W2317134147A5046756071 @default.
• W2317134147 hasAuthorship W2317134147A5052292682 @default.
• W2317134147 hasAuthorship W2317134147A5067684587 @default.
• W2317134147 hasAuthorship W2317134147A5069328349 @default.
• W2317134147 hasAuthorship W2317134147A5089047852 @default.
• W2317134147 hasAuthorship W2317134147A5090431664 @default.
• W2317134147 hasAuthorship W2317134147A5090483382 @default.
• W2317134147 hasConcept C121608353 @default.
• W2317134147 hasConcept C126322002 @default.
• W2317134147 hasConcept C126894567 @default.
• W2317134147 hasConcept C142724271 @default.
• W2317134147 hasConcept C168563851 @default.
• W2317134147 hasConcept C204787440 @default.
• W2317134147 hasConcept C27081682 @default.
• W2317134147 hasConcept C2775874879 @default.
• W2317134147 hasConcept C2776235491 @default.
• W2317134147 hasConcept C2779478474 @default.
• W2317134147 hasConcept C2779929075 @default.
• W2317134147 hasConcept C2780816001 @default.
• W2317134147 hasConcept C29456083 @default.
• W2317134147 hasConcept C3020768380 @default.
• W2317134147 hasConcept C71924100 @default.
• W2317134147 hasConcept C77411442 @default.
• W2317134147 hasConceptScore W2317134147C121608353 @default.
• W2317134147 hasConceptScore W2317134147C126322002 @default.
• W2317134147 hasConceptScore W2317134147C126894567 @default.
• W2317134147 hasConceptScore W2317134147C142724271 @default.
• W2317134147 hasConceptScore W2317134147C168563851 @default.
• W2317134147 hasConceptScore W2317134147C204787440 @default.
• W2317134147 hasConceptScore W2317134147C27081682 @default.
• W2317134147 hasConceptScore W2317134147C2775874879 @default.
• W2317134147 hasConceptScore W2317134147C2776235491 @default.
• W2317134147 hasConceptScore W2317134147C2779478474 @default.
• W2317134147 hasConceptScore W2317134147C2779929075 @default.
• W2317134147 hasConceptScore W2317134147C2780816001 @default.
• W2317134147 hasConceptScore W2317134147C29456083 @default.
• W2317134147 hasConceptScore W2317134147C3020768380 @default.
• W2317134147 hasConceptScore W2317134147C71924100 @default.
• W2317134147 hasConceptScore W2317134147C77411442 @default.
• W2317134147 hasIssue "4S" @default.
• W2317134147 hasLocation W23171341471 @default.
• W2317134147 hasOpenAccess W2317134147 @default.
• W2317134147 hasPrimaryLocation W23171341471 @default.
• W2317134147 hasRelatedWork W1518162929 @default.
• W2317134147 hasRelatedWork W2043131090 @default.
• W2317134147 hasRelatedWork W2101900205 @default.
• W2317134147 hasRelatedWork W2128138585 @default.
• W2317134147 hasRelatedWork W2166135155 @default.
• W2317134147 hasRelatedWork W2171549510 @default.
• W2317134147 hasRelatedWork W2315120746 @default.
• W2317134147 hasRelatedWork W2316944528 @default.
• W2317134147 hasRelatedWork W2332746632 @default.
• W2317134147 hasRelatedWork W2333932245 @default.
• W2317134147 hasRelatedWork W2335693928 @default.
• W2317134147 hasRelatedWork W2583509470 @default.
• W2317134147 hasRelatedWork W2602340387 @default.
• W2317134147 hasRelatedWork W2736497869 @default.
• W2317134147 hasRelatedWork W2739723941 @default.
• W2317134147 hasRelatedWork W2741093322 @default.
• W2317134147 hasRelatedWork W2794875804 @default.
• W2317134147 hasRelatedWork W2898545741 @default.
• W2317134147 hasRelatedWork W2900587173 @default.
• W2317134147 hasRelatedWork W2942070079 @default.
• W2317134147 hasVolume "189" @default.
• W2317134147 isParatext "false" @default.
• W2317134147 isRetracted "false" @default.
• W2317134147 magId "2317134147" @default.
• W2317134147 workType "article" @default.